Promising results of the largest of the Phase 2 studies were presented at this year’s annual meeting of the European Hematology Association (EHA). The data demonstrated that ZEVALIN therapeutic regimen following R-CHOP treatment resulted in a 5-year overall survival rate of 84% and 5-year progression-free survival of 75% in 44 older patients (age 62-86) with stage II-IV DLBCL . Overall survival was improved approximately 15% over that observed in similar risk patients treated with R-CHOP alone, 1 justifying confirmation of this finding in a larger randomized trial.“DLBCL consolidation therapy is a setting in which rituximab maintenance has failed to show benefit in two randomized clinical trials, whereas multiple Phase 2 studies have shown encouraging results for ZEVALIN consolidation in this setting. We feel that success of ZEVALIN in the ZEST study could lead to approval for its use in DLBCL consolidation therapy,” stated Dr. Shrotriya.
Spectrum Pharmaceuticals Initiates Phase 3 Study Of ZEVALIN® In Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL); Most Common Form Of Aggressive Non-Hodgkin’s Lymphoma
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.